Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 8/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
| ▸ | CXCR5 | P32302 | 1/20 | 0.41 |
| ▸ | APLNR | P35414 | 1/20 | 0.41 |
| ▸ | CCR6 | P51684 | 1/20 | 0.41 |
| ▸ | GFER | P55789 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 7/20 | 0.39 |
| ▸ | MAPT | P10636 | 6/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | F2 | P00734 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | BCHE | P06276 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5100883 | 0.86 | MAPT (0.45) | RAB9AKMT2AHSP90AA1CXCR5APLNR | |
| SCHEMBL5094693 | 0.84 | RAB9A (0.43) | RAB9AKMT2AHSP90AA1CXCR5APLNR | |
| SCHEMBL5093456 | 0.75 | ALDH1A1 (0.34) | RAB9AKMT2AALDH1A1NPC1MAPT | |
| SCHEMBL5089393 | 0.73 | GAA (0.48) | RAB9AKMT2AALDH1A1HPGDNPC1 | |
| Hydrochloric Acid SCHEMBL5094689 | 0.72 | GAA (0.47) | RAB9AKMT2AALDH1A1HPGDNPC1 | |
| SCHEMBL6086161 | 0.69 | PKM (0.33) | RAB9AKMT2AHSP90AA1CXCR5APLNR | |
| SCHEMBL5100874 | 0.69 | RAB9A (0.48) | RAB9AKMT2AHSP90AA1CXCR5APLNR | |
| SCHEMBL7020671 | 0.68 | SMN1; SMN2 (0.49) | RAB9AKMT2AALDH1A1HPGDNPC1 | |
| SCHEMBL30354936 | 0.67 | ALDH1A1 (0.67) | RAB9AKMT2AHSP90AA1CXCR5APLNR | |
| SCHEMBL3381391 | 0.67 | ALDH1A1 (0.67) | RAB9AKMT2AHSP90AA1CXCR5APLNR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7425557-B2 | Inhibitors of glycogen synthase kinase 3 | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2008-09-16 | — | — | US | disclosed |
| US-7045519-B2 | Inhibitors of glycogen synthase kinase 3 | CHIRON CORPORATION (US) | 2006-05-16 | — | — | US | disclosed |
| US-7037918-B2 | Inhibitors of glycogen synthase kinase 3 | CHIRON CORPORATION (US) | 2006-05-02 | — | — | US | disclosed |
| US-20060089369-A1 | Inhibitors of glycogen synthase kinase 3 | CHIRON CORPORATION (US) | 2006-04-27 | — | — | US | disclosed |
| US-20030130289-A1 | Inhibitors of glycogen synthase kinase 3 | CHIRON CORPORATION | 2003-07-10 | — | — | US | disclosed |
| US-6489344-B1 | FOR TREATMENT DIABETES IN A HUMAN OR ANIMAL SUBJECT | CHIRON CORPORATION | 2002-12-03 | — | — | US | disclosed |
| US-20020156087-A1 | Inhibitors of glycogen synthase kinase 3 | CHIRON CORPORATION | 2002-10-24 | — | — | US | disclosed |
| US-6417185-B1 | HETEROCYCLIC ENZYME INHIBITORS | CHIRON CORPORATION | 2002-07-09 | — | — | US | disclosed |
| EP-1087963-A1 | INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 | Chiron Corporation (US) | 2001-04-04 | — | — | EP | disclosed |
| WO-1999065897-A1 | INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 | CHIRON CORPORATION (US) | 1999-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130289-A1 | Inhibitors of glycogen synthase kinase 3 | GSK3B, GSK3A, PYGB | RAB9A 4060/4885KMT2A 3490/4885HSP90AA1 1457/4885 |
| US-20060089369-A1 | Inhibitors of glycogen synthase kinase 3 | GSK3B, GSK3A, PYGB | RAB9A 4093/4885KMT2A 3652/4885HSP90AA1 1343/4885 |
| US-20020156087-A1 | Inhibitors of glycogen synthase kinase 3 | GSK3B, GSK3A, PYGB | RAB9A 4093/4885KMT2A 3652/4885HSP90AA1 1343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.